Phase to phase: Navigating drug combinations with hypomethylating agents in higher-risk MDS trials for optimal outcomes

Merz, Almuth Maria Anni; Sébert, Marie; Sonntag, Jan; Kubasch, Anne Sophie; Platzbecker, Uwe; Adès, Lionel

doi:10.1016/j.ctrv.2023.102673

Cited by 4 publications

(3 citation statements)

References 88 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is a nucleoside analogue of cytidine that can specifically trap DNMT and thus achieve the effect of inhibiting DNA methylation (Raslan and Garcia-Horton, 2022). Azacitidine is mainly used to treat myelodysplastic syndromes (MDS) (Merz et al, 2024). The other drug approved by the FDA is decitabine (Myasoedova et al, 2019).…”

Section: Nucleoside Inhibitorsmentioning

confidence: 99%

Research progress and applications of epigenetic biomarkers in cancer

Gao,

Shi,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

Epigenetic changes are heritable changes in gene expression without changes in the nucleotide sequence of genes. Epigenetic changes play an important role in the development of cancer and in the process of malignancy metastasis. Previous studies have shown that abnormal epigenetic changes can be used as biomarkers for disease status and disease prediction. The reversibility and controllability of epigenetic modification changes also provide new strategies for early disease prevention and treatment. In addition, corresponding drug development has also reached the clinical stage. In this paper, we will discuss the recent progress and application status of tumor epigenetic biomarkers from three perspectives: DNA methylation, non-coding RNA, and histone modification, in order to provide new opportunities for additional tumor research and applications.

show abstract

Section: Nucleoside Inhibitorsmentioning

confidence: 99%

Research progress and applications of epigenetic biomarkers in cancer

Gao,

Shi,

Wang

et al. 2024

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…Compared to LR-MDS, the clinical management of HR patients significantly differs, in line with the AML approach [2,62,63], aiming at modifying the natural disease history, prolonging survival [80,81], and possibly achieving adequate disease control or cure through allogenic STC, which should be considered early in the disease course and promptly proposed to eligible patients [66][67][68]. HMAs, given with a life-prolonging intent and/or to reduce disease burden for subsequent allogeneic SCT, are still currently the standard of care for patients with HR-MDS [62,63,[103][104][105]. Figure 3 reports the current clinical practice of difficult-to-treat patients [62].…”

Section: Higher-risk Mdsmentioning

confidence: 99%

“…However, only around half of patients respond to these agents. In addition, responses are transient and generally last less than two years [104,105]. Thus far, several novel agents with different mechanisms of action have been tested, mostly in association with HMAs, to improve the treatment efficacy in HR-MDS [103].…”

Section: Higher-risk Mdsmentioning

confidence: 99%

Latest Insights and Therapeutic Advances in Myelodysplastic Neoplasms

Niscola,

Gianfelici,

Giovannini

et al. 2024

Cancers

View full text Add to dashboard Cite

Myelodysplastic syndromes/neoplasms (MDSs) encompass a range of hematopoietic malignancies, commonly affecting elderly individuals. Molecular alterations in the hematopoietic stem cell compartment drive disease pathogenesis. Recent advancements in genomic profiling have provided valuable insights into the biological underpinnings of MDSs and have expanded therapeutic options, particularly for specific molecularly defined subgroups. This review highlights the diagnostic principles, classification updates, prognostic stratification systems, and novel treatments, which could inform future clinical trials and enhance the management of adult MDS patients, particularly for specific molecularly defined subgroups.

show abstract